FDG-PET最大标准化摄取值、基因标记与临床病理风险因素联合分析用于切除性口腔鳞状细胞癌预后分层
该回顾性研究纳入2036例首次原发口腔鳞状细胞癌手术患者,其中327例具备FDG-PET、基因标记和临床病理风险因素的完整数据。研究确定原发肿瘤和颈部转移淋巴结SUV-max的最佳截断值分别为22.8和9.7,联合基因 Panel 阳性及 pN3b 疾病构建评分系统,可将患者分为四个预后显著不同的组别。
要点
- 原发肿瘤SUV-max≥22.8或淋巴结SUV-max≥9.7与5年DFS显著降低相关(32% vs 62%,P<0.001)。
- UDTS/WES基因 Panel 阳性与阴性者5年DFS分别为25%和62%(P<0.001)。
- 基于SUV-max、基因标记和pN3b的评分系统可区分四组,5年DFS从74%降至7%。
核心结论
- 联合评估肿瘤和淋巴结SUV-max、基因标记及病理淋巴结状态可优化口腔鳞状细胞癌患者的预后分层。
研究设计与样本
- 回顾性分析了1996至2016年间2036例首次原发口腔鳞状细胞癌手术患者的临床记录。
- 其中345例接受超深度靶向测序(1996-2011年),168例接受全外显子测序(2007-2016年),1135例于2001至2016年术前行FDG-PET。
- 327例患者具备FDG-PET、基因标记和临床病理风险因素的完整数据。
主要发现
- 基于5年无病生存(DFS)的log-rank检验确定原发肿瘤和颈部转移淋巴结SUV-max最佳截断值分别为22.8和9.7。
- SUVtumor-max≥22.8或SUVnodal-max≥9.7组(n=77)与两者均低于截断值组(n=250)的5年DFS分别为32%和62%(P<0.001)。
- UDTS或WES基因 Panel 阳性组(n=64)与阴性组(n=263)的5年DFS分别为25%和62%(P<0.001)。
- pN3b组(n=165)与pN1-2组(n=162)的5年DFS分别为42%和68%(P<0.001)。
- 多因素分析中,SUVtumor-max≥22.8或SUVnodal-max≥9.7、UDTS/WES基因 Panel 阳性及pN3b疾病是5年结局的独立预后因素。
关键数值与推荐
- 评分0至3分患者的5年局部区域控制率分别为80%/67%/47%/24%(P<0.001)。
- 评分0至3分患者的5年远处转移率分别为13%/23%/55%/92%(P<0.001)。
- 评分0至3分患者的5年DFS分别为74%/58%/28%/7%(P<0.001)。
- 评分0至3分患者的5年疾病特异性生存率分别为80%/64%/35%/7%(P<0.001)。
临床怎么用
- 对切除性口腔鳞状细胞癌患者,可综合术前FDG-PET的肿瘤和淋巴结SUV-max、基因 Panel 结果及病理淋巴结状态进行预后评分。
- 依据评分将患者分为四个预后组,辅助识别高危患者以指导术后随访和治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clinical outcomes of patients with resected oral cavity squamous cell carcinoma (OCSCC) chiefly depend on the presence of specific clinicopathological risk factors (RFs). Here, we performed a combined analysis of FDG-PET, genetic markers, and clinicopathological RFs in an effort to improve prognostic stratification. METHODS: We retrospectively reviewed the clinical records of 2036 consecutive patients with first primary OCSCC who underwent surgery between 1996 and 2016. Of them, 345 underwent ultra-deep targeted sequencing (UDTS, between 1996 and 2011) and 168 whole exome sequencing (WES, between 2007 and 2016). Preoperative FDG-PET imaging was performed in 1135 patients from 2001 to 2016. Complete data on FDG-PET, genetic markers, and clinicopathological RFs were available for 327 patients. RESULTS: Using log-ranked tests based on 5-year disease-free survival (DFS), the optimal cutoff points for maximum standardized uptake values (SUV-max) of the primary tumor and neck metastatic nodes were 22.8 and 9.7, respectively. The 5-year DFS rates were as follows: SUVtumor-max ≥ 22.8 or SUVnodal-max ≥ 9.7 (n = 77) versus SUVtumor-max < 22.8 and SUVnodal-max < 9.7 (n = 250), 32%/62%, P < 0.001; positive UDTS or WES gene panel (n = 64) versus negative (n = 263), 25%/62%, P < 0.001; pN3b (n = 165) versus pN1-2 (n = 162), 42%/68%, P < 0.001. On multivariate analyses, SUVtumor-max ≥ 22.8 or SUVnodal-max ≥ 9.7, a positive UDTS/WES gene panel, and pN3b disease were identified as independent prognosticators for 5-year outcomes. Based on these variables, we devised a scoring system that identified four distinct prognostic groups. The 5-year rates for patients with a score from 0 to 3 were as follows: loco-regional control, 80%/67%/47%/24% (P < 0.001); distant metastases, 13%/23%/55%/92% (P < 0.001); DFS, 74%/58%/28%/7% (P < 0.001); and disease-specific survival, 80%/64%/35%/7% (P < 0.001) respectively. CONCLUSIONS: The combined assessment of tumor and nodal SUV-max, genetic markers, and pathological node status may refine the prognostic stratification of OCSCC patients.
引用
- Liao CT, Hsieh CH, Fan WL, et al. A combined analysis of maximum standardized uptake value on FDG-PET, genetic markers, and clinicopathological risk factors in the prognostic stratification of patients with resected oral cavity squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2019. PMID: 31388722. doi:10.1007/s00259-019-04453-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。